{"disease":{"id":"malignant-glioma","name":"Malignant glioma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":14},"drugs":{"marketed":[{"drug_id":"sitravatinib","indication_name":"Malignant glioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sitravatinib","generic_name":"sitravatinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine kinases","drug_class":"Tyrosine kinase inhibitor","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05100173","title":"Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1192,"lead_sponsor_name":"Genetron Health","has_results":false},{"nct_id":"NCT07448480","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Blokhin's Russian Cancer Research Center","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06914700","title":"A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators:","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT02300532","title":"Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)","phase":"","overall_status":"COMPLETED","enrollment_count":561,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT02300506","title":"Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma","phase":"","overall_status":"COMPLETED","enrollment_count":507,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT02526017","title":"Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Five Prime Therapeutics, Inc.","has_results":true},{"nct_id":"NCT00924196","title":"Natural History Study of Patients With Neurofibromatosis Type I","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":259,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04732065","title":"ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"Sabine Mueller, MD, PhD","has_results":false},{"nct_id":"NCT06132685","title":"Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT06630260","title":"5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":182,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT02465268","title":"Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"University of Florida","has_results":true},{"nct_id":"NCT02721732","title":"Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":157,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT00103038","title":"Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases","phase":"NA","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":true},{"nct_id":"NCT05099003","title":"A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05538130","title":"A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02330562","title":"Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT02986178","title":"Lerapolturev in Recurrent Malignant Glioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Istari Oncology, Inc.","has_results":true},{"nct_id":"NCT04109209","title":"Psychological Intervention For Brain Tumor Caregivers","phase":"NA","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06470711","title":"Mapping of Electrical Properties in the Brain","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06989086","title":"FearLess in NeuroOncology","phase":"NA","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"Virginia Commonwealth University","has_results":false},{"nct_id":"NCT03423992","title":"Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT06099743","title":"ASCENT Intervention for Brain Tumor Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05873946","title":"Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Hospital del Rio Hortega","has_results":false},{"nct_id":"NCT01266031","title":"Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03212742","title":"Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":91,"lead_sponsor_name":"Centre Francois Baclesse","has_results":false},{"nct_id":"NCT03212274","title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":89,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06417281","title":"Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA）","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT00272350","title":"ZD6474 to Treat Advanced Brain Cancer in Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02303678","title":"D2C7 for Adult Patients With Recurrent Malignant Glioma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Darell Bigner","has_results":false},{"nct_id":"NCT04771806","title":"Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03033992","title":"Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03749187","title":"BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":78,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT01371201","title":"First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT06270082","title":"Study of IK-595 in RAS- or RAF-altered Advanced Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":75,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT04541225","title":"Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT03244995","title":"Mind-Body Intervention in Glioma Couples","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02020720","title":"18F-DOPA-PET in Planning Surgery in Patients With Gliomas","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02359565","title":"Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":71,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03893903","title":"AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"German Cancer Research Center","has_results":false},{"nct_id":"NCT03434262","title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT02903069","title":"Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT05857969","title":"Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":65,"lead_sponsor_name":"Florida International University","has_results":false},{"nct_id":"NCT02661282","title":"Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02208362","title":"Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":65,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT07391215","title":"5G-PEARL: Paxalisib in Malignant Brain Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT04870944","title":"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":63,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03718767","title":"Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}